一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Dalpicilib；endocrine therapy，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Dalpicilib；endocrine therapy · III 期
登记条件中文摘要
年龄范围：18岁至70岁
登记的基本范围为女性，年龄18岁至70岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- breast cancer institute of Fudan University Cancer Hospital, shanghai, shanghai · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Women aged 18-70 years
- 2. ECOG score of 0-1
- 3. Histologically confirmed unilateral invasive cancer (regardless of pathology type)
- 4. No macroscopic or microscopic tumor residue after surgical resection
- 5. Early-stage breast cancer, pathologically confirmed as ER-positive and HER2-negative (ER-positive defined as immunohistochemical detection of ER \>10% of tumor cells positive; HER2 0-1+ or HER2 2+ but FISH negative, with no amplification, defined as HER2-negative)
- 6. Postoperative pathological staging of pT1c or above, N0M0, and meeting one of the following criteria: (1) G3; (2) G2 and meeting one of the following: i. Ki-67 ≥20%; ii. 21-gene recurrence score ≥26 or high genomic risk profile; iii. Age ≤40 years and vascular invasion positive
- 7. No prior neoadjuvant treatment
- 8. Time from surgery or completion of chemotherapy or radiotherapy (whichever occurs later) to randomization does not exceed 8 weeks
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06637150；登记信息更新于 2026-09-29；本站同步于 2026-10-08，中国中心当前名额未经人工确认。